Search research articles
Contact Us
Filters
Showing results (201-210 of 204) with videos related to
Page
of 21
Sort By:
You have reached the last page of results.
This site can display upto 204 results.
Blood
|
February 17, 2023
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
Andrew J Dunbar, Dongjoo Kim, Min Lu, et al.
Cancer Cell
|
July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Blood
|
January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Blood
|
June 29, 2022
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A Arber, Attilio Orazi, Robert P Hasserjian, et al.
Page
of 21
Search research articles
Search
Showing results (201-210 of 204) with videos related to
Sort By:
Page
of 21
You have reached the last page of results.
This site can display upto 204 results.
Blood
|
February 17, 2023
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
Andrew J Dunbar, Dongjoo Kim, Min Lu, et al.
Cancer Cell
|
July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Blood
|
January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
John Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Blood
|
June 29, 2022
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A Arber, Attilio Orazi, Robert P Hasserjian, et al.
Page
of 21